Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group

被引:2
|
作者
Motomura, Kazuya [1 ]
Sasaki, Keita [2 ]
Sugii, Narushi [3 ]
Yamaguchi, Shigeru [4 ]
Inoue, Hirotaka [5 ]
Oshima, Akito [6 ]
Tanaka, Kazuhiro [7 ]
Otani, Yoshihiro [8 ]
Shirahata, Mitsuaki [9 ]
Shibahara, Ichiyo [10 ]
Nagane, Motoo [11 ]
Tsuzuki, Shunsuke [12 ]
Matsutani, Tomoo [13 ]
Tsukamoto, Yoshihiro [14 ]
Kijima, Noriyuki [15 ]
Asano, Kenichiro [16 ]
Ohno, Makoto [17 ]
Inoue, Akihiro [18 ]
Mineharu, Yohei [19 ]
Miyake, Keisuke [20 ]
Mitobe, Yuta [21 ]
Hanihara, Mitsuto [22 ]
Kawanishi, Yu [23 ]
Deguchi, Shoichi [24 ]
Saito, Masato [25 ]
Matsuda, Ryosuke [26 ]
Ujifuku, Kenta [27 ]
Arita, Hideyuki [28 ]
Sato, Yuichi [29 ]
Yamashita, Shinji [30 ]
Yonezawa, Ushio [31 ]
Yamaguchi, Junya [1 ]
Momii, Yasutomo [32 ]
Ogawa, Takahiro [33 ]
Kambe, Atsushi [34 ]
Ohba, Shigeo [35 ]
Fukai, Junya [36 ]
Saito, Norihiko [37 ]
Kinoshita, Masashi [38 ]
Sumi, Koichiro [39 ]
Otani, Ryohei [40 ]
Uzuka, Takeo [41 ]
Takebe, Noriyoshi [42 ]
Koizumi, Shinichiro [43 ]
Saito, Ryuta [1 ]
Arakawa, Yoshiki [19 ]
Narita, Yoshitaka [17 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Neurosurg, 65 Tsurumai Co,Showa Ku, Nagoya, Japan
[2] JCOG Data Ctr, Natl Canc Ctr Hosp, Operat Off, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan
[3] Univ Tsukuba Hosp, Dept Neurosurg, 2-1-1 Amakubo, Tsukuba, Japan
[4] Hokkaido Univ, Fac Med, Dept Neurosurg, North 15,West 7,Kita Ku, Sapporo, Japan
[5] Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, 1-1-1,Honjo,Chuo Ku, Kumamoto, Japan
[6] Yokohama City Univ, Dept Neurosurg, 3-9 Fukuura, Kanazawa, Yokohama, Japan
[7] Kobe Univ Hosp, Dept Neurosurg, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Japan
[8] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Dept Neurol Surg, 2-5-1 Shikata Cho,Kita Ku, Okayama, Japan
[9] Med Univ Int Med Ctr, Dept Neurosurg Neurooncol, 1397-1 Yamane,Hidaka, Saitama, Saitama, Japan
[10] Kitasato Univ, Dept Neurosurg, Sch Med, 1-15-1,Minami Ku,Sagamihara, Kitasato, Japan
[11] Kyorin Univ, Fac Med, Dept Neurosurg, 6-20-2 Shinkawa, Tokyo, Japan
[12] Tokyo Womens Med Univ, Dept Neurosurg, 8-1 Kawada-Cho,Shinjuku Ku, Tokyo, Japan
[13] Chiba Univ, Grad Sch Med, Dept Neurol Surg, 1-8-1 Inohana,Chuou Ku, Chiba, Japan
[14] Niigata Univ, Brain Res Inst, Dept Neurosurg, 1-757 Asahimachi Dori,Chuo Ku, Niigata, Japan
[15] Osaka Univ, Grad Sch Med, Dept Neurosurg, 2-2 Yamadaoka,Suita, Osaka, Japan
[16] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Zaifu Cho 5, Hirosaki, Japan
[17] Natl Canc Ctr, Dept Neurosurg & Neurooncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan
[18] Ehime Uunivers, Sch Med, Dept Neurosurg, 454 Shitsukawa, Toon, Ehime, Japan
[19] Kyoto Univ, Grad Sch Med, Dept Neurosurg, 54 Kawahara Cho,Shogoin Sakyo Ku, Kyoto, Japan
[20] Kagawa Univ, Fac Med, Dept Neurol Surg, 1750-1 Ikenobe,Miki Cho, Kagawa, Japan
[21] Yamagata Univ Hosp, Dept Neurosurg, 2-2-2 Iida-Nishi, Yamagata, Japan
[22] Univ Yamanashi, Dept Neurosurg, 1110 Shimokato, Kofu, Yamanashi, Japan
[23] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Oko Cho,Nanko Ku, Kohasu, Kochi, Japan
[24] Shizuoka Canc Ctr, Dept Neurosurg, Shimonagakubo 1007, Nagaizumi, Shizuoka, Japan
[25] Asahikawa Med Univ, Dept Neurosurg, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Japan
[26] Nara Med Univ, Dept Neurosurg, Shijo Cho 840, Kashihara, Nara, Japan
[27] Nagasaki Univ, Grad Sch Biomed Sci, Dept Neurosurg, 1-7-1 Sakamoto, Nagasaki, Japan
[28] Osaka Int Canc Inst, Dept Neurosurg, 3-1-69, Otemae, Chuo Ku, Osaka, Japan
[29] Iwate Med Univ, Sch Med, Dept Neurosurg, 2-1-1 Idai Dori, Shiwa, Iwate, Japan
[30] Miyazaki Univ, Dept Neurosurg, 5200 Kihara Kiyotake, Miyazaki, Japan
[31] Hiroshima Univ Hosp, Dept Neurosurg, 1-2-3 Minami Ku, Kasumi, Hiroshima, Japan
[32] Oita Univ, Fac Med, Dept Neurosurg, 1-1 Idaigaoka Hasama Machi, Yufu, Oita, Japan
[33] Kyoto Prefectural Univ Med, Dept Neurosurg, 465 Kajii Cho,Kawaramachi-Hirokoji,Kamigyo Ku, Kyoto, Japan
[34] Tottori Univ, Fac Med, Dept Brain & Neurosci, Div Neurosurg, 36-1 Nishi Cho, Yonago, Tottori, Japan
[35] Fujita Hlth Univ, Dept Neurosurg, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi, Japan
[36] Wakayama Med Univ, Sch Med, Dept Neurol Surg, 811-1 Kimiidera, Wakayama, Japan
[37] Toho Univ, Ohashi Med Ctr, Dept Neurosurg, 2-22-36 Ohashi, Meguro, Tokyo, Japan
[38] Kanazawa Univ, Dept Neurosurg, 13-1 Takara Machi, Kanazawa, Japan
[39] Nihon Univ, Sch Med, Dept Neurol Surg, 30-1 Oyaguchikamicho,Itabashi Ku, Tokyo, Japan
[40] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Neurosurg, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo, Japan
[41] Dokkyo Med Univ Hosp, Dept Neurosurg, 880 Kitakobayashi,Mibu Machi, Tochigi, Japan
[42] Med Res Inst Kitano Hosp, Dept Neurosurg, PIIF Tazuke Kofukai, 2-4-20 Ohgimachi,Kita-Ku, Osaka, Japan
[43] Hamamatsu Univ Sch Med, Dept Neurosurg, 1-20-1 Handayama,Higashi Ku, Hamamatsu, Shizuoka, Japan
关键词
glioblastoma; primary central nervous system lymphoma; treatment regimen; high-cost medical care; cost; HIGH-DOSE METHOTREXATE; RANDOMIZED PHASE-III; CHEMOTHERAPY; TEMOZOLOMIDE; GLIOBLASTOMA; RADIOTHERAPY; TRIAL; BEVACIZUMAB; CONCOMITANT; RITUXIMAB;
D O I
10.1093/jjco/hyae116
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved.Methods We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL.Results The most used regimen (46.8%) for GBM in patients aged <= 74 years was 'Surgery + radiotherapy concomitant with temozolomide'. This regimen's total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, 'Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy' was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month).Conclusions Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors. As regimens used in GBM or PCNSL are costly, we believe that it will be necessary in the future to take cost-effectiveness into consideration in selecting a treatment.
引用
收藏
页码:1123 / 1131
页数:9
相关论文
共 50 条
  • [31] MULTIDISCIPLINARY MEDICAL CARE SYSTEM FOR BRAIN TUMOR SURVIVORS IN JAPAN
    Saito, Norihiko
    Hirai, Nozomi
    Koyahara, Yuki
    Sato, Sho
    Hiramoto, Yu
    Fujita, Satoshi
    Nakayama, Haruo
    Hayashi, Morito
    Izukura, Hideaki
    Sakurai, Takatoshi
    Iwabuchi, Satoshi
    NEURO-ONCOLOGY, 2023, 25
  • [32] RISK-FACTORS FOR TUMORS OF THE BRAIN AND MENINGES - RESULTS FROM THE ADELAIDE ADULT BRAIN-TUMOR STUDY
    RYAN, P
    LEE, MW
    NORTH, JB
    MCMICHAEL, AJ
    INTERNATIONAL JOURNAL OF CANCER, 1992, 51 (01) : 20 - 27
  • [33] A case–control study of childhood brain tumors and fathers’ hobbies: a Children’s Oncology Group study
    Andrea L. Rosso
    Mary E. Hovinga
    Lucy B. Rorke-Adams
    Logan G. Spector
    Greta R. Bunin
    Cancer Causes & Control, 2008, 19 : 1201 - 1207
  • [34] Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237
    Dreyer, ZE
    Kadota, RP
    Stewart, CF
    Friedman, HS
    Mahoney, DH
    Kun, LE
    McCluggage, CW
    Burger, PC
    Kepner, J
    NEURO-ONCOLOGY, 2003, 5 (04) : 261 - 267
  • [35] Nationwide Application of an Integrated Diagnosis System for Pediatric Brain Tumors in Clinical Settings: The Japan Children's Cancer Group (JCCG) Brain Tumor Committee Initiative
    Nakano, Y.
    Ichimura, K.
    Kanemura, Y.
    Hirato, J.
    Takako, Y.
    Nobusawa, S.
    Kitahara, M.
    Shofuda, T.
    Yamasaki, K.
    Fukuoka, K.
    Sakamoto, H.
    Nishikawa, R.
    Hara, J.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S448 - S449
  • [36] HYPERFRACTIONATED RADIOTHERAPY IN BRAIN-STEM TUMORS - RESULTS OF A PEDIATRIC ONCOLOGY GROUP-STUDY
    FREEMAN, CR
    KRISCHER, J
    SANFORD, RA
    BURGER, PC
    COHEN, M
    NORRIS, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (02): : 311 - 318
  • [37] SUPERIORITY OF PCNU OVER AZQ IN THE TREATMENT OF PRIMARY BRAIN-TUMORS - RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL-(81-20) BY THE BRAIN-TUMOR STUDY-GROUP
    MALKIN, MG
    GREEN, SB
    BYAR, DP
    STRIKE, TA
    BURGER, PC
    VOGEL, FS
    PISTENMAA, DA
    MAHALEY, MS
    RANSOHOFF, J
    SHAPIRO, WR
    MEALEY, J
    ROBERTSON, JT
    SELKER, RG
    VANGILDER, JC
    JOURNAL OF NEURO-ONCOLOGY, 1994, 22 (01) : 55 - 65
  • [38] The History of the Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG)
    Onda, Takashi
    Konishi, Ikuo
    Yoshikawa, Hiroyuki
    Kamura, Toshiharu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (10) : 1156 - 1161
  • [39] AZIRIDINYLBENZOQUINONE (AZQ) IN THE TREATMENT OF RECURRENT PEDIATRIC BRAIN AND OTHER MALIGNANT SOLID TUMORS - A PEDIATRIC ONCOLOGY GROUP PHASE-II STUDY
    CASTLEBERRY, RP
    RAGAB, AH
    STEUBER, CP
    KAMEN, B
    TOLEDANO, S
    STARLING, K
    NORRIS, D
    BURGER, P
    KRISCHER, JP
    INVESTIGATIONAL NEW DRUGS, 1990, 8 (04) : 401 - 406
  • [40] Towards Improved Medical Imaging Analysis for Oncology Care: Clinical Experience with Simulation Platform for Brain Tumors
    Hajra, S. Ghosh
    Liu, C.
    Sepehri, K.
    Proulx, R.
    Song, X.
    Badragan, I.
    D'Arcy, R.
    Murray, D.
    Krauze, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E794 - E794